[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Rarecells Diagnostics SAS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":5},"100558045","rarecells-molecular-biomarkers-for-early-detection-of-lung-cancer-100558045",false,"NCT06546007","Rarecells Molecular Biomarkers for Early Detection of Lung Cancer","Clinical Study To Evaluate the Sensitivity of Circulating Iset® by Rarecells Molecular Biomarkers for Early Detection of Lung Cancer","BioMolCTC","Inclusion Criteria:\n\n1. Male or female aged between 35 and 85 years\n2. Patient diagnosed with resectable lung cancer (by imaging and\u002For pathological examination) not yet treated for this cancer.\n3. Patient capable of giving free, informed, and express consent\n\nThe assessment of successful elected surgery implies, but is not limited to, the following:\n\n* Exclusion of detectable extra thoracic and distant metastases\n* Determination of the presence or absence of superior mediastinal lymph node metastases\n* Definition of the histologic or cell type, whenever possible\n* Evaluation of operative risk\n\nExclusion Criteria:\n\n1. Patient diagnosed and\u002For treated previously for lung cancer or another cancer, regardless of duration\n2. Patient treated with neoadjuvant treatment\n3. Pregnant women\n4. Patient presenting psychiatric or neurological disorders preventing them from understanding the research","ALL","35 Years","85 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","Early diagnosis of lung cancer is a public health priority. Additionally, early detection of recurrences after treatment is crucial for optimizing disease management.\n\nThis study seeks to demonstrate the accuracy of the Rarecells ISET® circulating tumor cells DNA (CTC-DNA), combined with circulating tumor DNA (ctDNA), for the early diagnosis of lung cancer.",[26,27],"Lung Cancer","Pulmonary Neoplasm",[29,30,31,32],"Circulating tumor cells","Lung cancer","Circulating tumor DNA","Pulmonary neoplasm","RECRUITING","2025-06-10",{"date":36,"type":37},"2025-06-11","ACTUAL",{"date":39,"type":37},"2024-11-13",{"date":41,"type":22},"2025-10-01",{"name":43,"class":44},"Rarecells Diagnostics SAS","INDUSTRY",""]